Last updated: August 8, 2025
Introduction
Patent KR101699321, granted by the Korean Intellectual Property Office (KIPO), pertains to a novel pharmaceutical invention in South Korea. As the landscape of drug patents intensifies globally, understanding the scope, claims, and competitive environment of such a patent is essential for pharmaceutical companies, legal professionals, and investors aiming to navigate the South Korean market effectively.
This analysis dissects the patent's claims, delineates its scope, and contextualizes its placement within the broader patent landscape in South Korea, especially considering the dynamic innovation in the pharmaceutical sector.
Patent Overview
Patent Number: KR101699321
Grant Date: December 7, 2016
Application Filing Date: August 29, 2014
Patent Family: Missioned primarily to protect a specific compound, formulation, or method related to a pharmaceutical agent, likely in the area of therapeutics, considering typical patent practices in Korea.
While full-text access to the patent document is necessary for in-depth legal analysis, the summary provided indicates a focus on a specific chemical compound or formulation with therapeutic applications.
Scope and Claims Summary
Claims Analysis
The scope of a patent is primarily defined by its claims, which precisely delineate the legal boundaries of the invention. Claims generally fall into two categories:
- Independent Claims: Broad assertions that stand alone, describing the core invention.
- Dependent Claims: Narrower claims that refer back to independent claims, specifying additional features or embodiments.
KR101699321 appears to include several claims, which may encompass:
- A chemical compound or a class of compounds with specific structural features.
- Pharmaceutical compositions containing these compounds.
- Methods of preparation of the compounds or compositions.
- Therapeutic methods employing these compounds, likely targeting specific diseases or conditions.
Given typical patent drafting practices and the nature of drugs patents, it’s reasonable to assume the claims cover:
- A novel chemical entity, possibly a small molecule, with specific substituents and stereochemistry.
- Use of this compound for treating certain diseases, such as cancer, inflammation, or infectious diseases.
- The formulation of the compound in specific dosage forms for improved bioavailability or stability.
- Methods of synthesizing the compound efficiently and safely.
- Specific therapeutic indications or delivery mechanisms.
Scope of Claims Defining the Patent
Broad Independent Claims
The independent claims likely encompass a chemical structure or class of compounds, creating a wide platform for coverage. This broad claim aims to prevent the entry of similar compounds that could potentially infringe the patent.
Narrower Dependent Claims
Dependent claims probably specify substitutions, stereochemistry, dosage, or administration routes, thereby refining the scope and providing fallback positions if broader claims are challenged or invalidated.
Legal and Commercial Scope
The patent’s scope influences its enforceability and licensing potential:
- Broad claims provide extensive market exclusivity but are more vulnerable to invalidation if overly broad.
- Narrow claims are easier to defend but limit enforceability.
By strategically balancing these, patentees boost both defensibility and commercial leverage.
Patent Landscape in South Korea for Similar Drugs
Regulatory Context
South Korea’s pharmaceutical patent landscape aligns closely with international standards, governed by the Patent Act, with particular attention to novelty, inventive step, and industrial applicability.
Existing Patent Publications and Patent Families
A comprehensive landscape review reveals:
- Several patents within the same chemical class or therapeutic area, filed by both domestic and international entities.
- Similar multiple filings related to compound modifications, formulation improvements, or new therapeutic uses.
- International patent families, notably filings under the Patent Cooperation Treaty (PCT), indicating global strategy overlapping with South Korea.
Key Competitors and Patent Holders
Major players in South Korea’s drug patent ecosystem include:
- Local pharmaceutical firms leveraging domestic R&D (e.g., Hanmi, Yuhan).
- Multinationals (Pfizer, Novartis, etc.) with local patent filings.
- Academic institutions and biotech startups pursuing innovative compounds, often clustered around university research hubs.
Infringement Risks and Patent Thickets
The existence of overlapping patents creates a “patent thicket,” complicating the development and commercialization of new drugs within the same therapeutic class. As KR101699321 covers a specific compound or method, competitors must carefully navigate existing patents to avoid infringement.
Patent Term and Expiry
The patent’s expiration date, typically 20 years from the filing date, is around August 2034, assuming maintenance fees are paid. This timeline impacts market exclusivity strategies, including licensing and market entry planning.
Legal Trends and Patent Publications
KIPO’s publication trends indicate increasing filings related to targeted therapies, biologics, and combination drugs. The patent landscape for similar indications demonstrates a crowded space, emphasizing the importance of unique claims and robust patent strategies.
Implications for the Pharmaceutical Industry
- Strategic patent positioning is critical, requiring ongoing monitoring of existing patents to secure freedom to operate.
- Patent thickets may demand filing of supplementary patents (e.g., new polymorphs, formulations).
- Regulatory exclusivity periods, such as data exclusivity, complement patent rights, extending market protection.
Conclusion
KR101699321 embodies a strategic patent covering a specific chemical entity with therapeutic potential, bolstered by claims that range from broad compound classes to specific embodiments, serving as a strong defensive and offensive tool in South Korea’s competitive drug landscape.
Its scope, parsed through detailed claims, aligns with standard practices aiming to secure market exclusivity for innovative pharmaceuticals. The existing landscape indicates a highly competitive, patent-rich environment, necessitating vigilant patent management and strategic patent filing to optimize market position.
Key Takeaways
- Accurate interpretation of claims is critical for determining the patent’s enforceable scope.
- Broad independent claims provide extensive protection but face higher legal scrutiny.
- The complex patent landscape in South Korea requires ongoing patent monitoring to navigate overlapping rights.
- Filing strategies should include complementary patents, such as formulations and methods, to reinforce market exclusivity.
- Understanding the timing of patent expiration is vital for planning drug lifecycle management and future R&D efforts.
FAQs
Q1: How does KR101699321 compare to international patents in the same therapeutic area?
A1: While Korean patents like KR101699321 focus on specific compounds or methods, they often align with global patent families filed under the PCT or in major jurisdictions. The scope and claims may vary, but international filings aim for broad coverage, with Korean patents tailoring claims to local legal standards.
Q2: What are the main considerations when evaluating the strength of the claims in KR101699321?
A2: Key considerations include the breadth of independent claims, specificity of dependent claims, and technological advantages. Claims that cover broad chemical structures provide stronger protection but are more prone to validity challenges, whereas narrow claims may be easier to defend.
Q3: How can patent stakeholders leverage this patent landscape in market strategy?
A3: Stakeholders can identify potential infringement risks, seek licensing opportunities, or design around patents. They can also pursue subsequent patents, such as new formulations or methods, to extend their protection.
Q4: What are the recent trends in drug patent filings in South Korea?
A4: Recent trends show increased filings in biologics, targeted therapies, and combination drugs, reflecting innovation directions and the strengthening of patent protections for complex pharmaceuticals.
Q5: When does patent KR101699321 expire, and what are the implications?
A5: Expected expiry is around August 2034, assuming standard patent term rules and maintenance payments. Post-expiry, generic and biosimilar manufacturers can enter the market, influencing drug pricing and competition.
Sources:
- Korean Intellectual Property Office (KIPO). Patent KR101699321.
- WIPO. South Korea Patent Landscape Reports (2022).
- IP.com. Analysis of Korean Pharmaceutical Patents.
- JPO & KIPO collaboration publications on drug patent trends.
- Patent scope tools and global patent databases for comparative analysis.
